- Home
- PMVP vs QNCX Comparison
PMVP vs QNCX Comparison
Compare PMVP & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- QNCX
- Stock Information
- Founded
- PMVP 2013
- QNCX 2012
- Country
- PMVP United States
- QNCX United States
- Employees
- PMVP N/A
- QNCX N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMVP Health Care
- QNCX Health Care
- Exchange
- PMVP Nasdaq
- QNCX Nasdaq
- Market Cap
- PMVP 55.1M
- QNCX 47.7M
- IPO Year
- PMVP 2020
- QNCX 2019
- Fundamental
- Price
- PMVP $1.09
- QNCX $1.31
- Analyst Decision
- PMVP Strong Buy
- QNCX Strong Buy
- Analyst Count
- PMVP 1
- QNCX 5
- Target Price
- PMVP $5.00
- QNCX $8.00
- AVG Volume (30 Days)
- PMVP 362.7K
- QNCX 304.4K
- Earning Date
- PMVP 08-07-2025
- QNCX 08-12-2025
- Dividend Yield
- PMVP N/A
- QNCX N/A
- EPS Growth
- PMVP N/A
- QNCX N/A
- EPS
- PMVP N/A
- QNCX N/A
- Revenue
- PMVP N/A
- QNCX N/A
- Revenue This Year
- PMVP N/A
- QNCX N/A
- Revenue Next Year
- PMVP N/A
- QNCX N/A
- P/E Ratio
- PMVP N/A
- QNCX N/A
- Revenue Growth
- PMVP N/A
- QNCX N/A
- 52 Week Low
- PMVP $0.81
- QNCX $0.51
- 52 Week High
- PMVP $1.82
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- PMVP 61.16
- QNCX 64.64
- Support Level
- PMVP $1.01
- QNCX $1.29
- Resistance Level
- PMVP $1.12
- QNCX $1.45
- Average True Range (ATR)
- PMVP 0.07
- QNCX 0.09
- MACD
- PMVP 0.01
- QNCX 0.03
- Stochastic Oscillator
- PMVP 64.00
- QNCX 76.74
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.